Physalis angulata ethanol extract
OtherEthanol extract of physalis angulate Linn with dosage of 3x250 mg/day given orally for 3 months
Other names: Herba Ciplukan, Ethanol extract of Physalis angulata Linn, Ethanol extract of Physalis angulata
NCT Number: NCT03141125
Study about the effect of ethanol extract physalis angulate in scleroderma patients with standard therapy to reduce skin fibrosis based on modified Rodnan Skin Score, reduce inflammation, immunological response and fibrosis: A Randomized Clinical Placebo ControlledTrial with a prospective cohort study on scleroderma outpatient clinic in Cipto Mangunkusumo Hospital in Jakarta and Hasan Sadikin Hospital in Bandung, from January 2016 to July 2017
Looking for future studies?
Notify Me18 year–60 year
All sexes
Interventional
Not applicable
Hasan Sadikin Hospital, Bandung, West Java, Indonesia
Background.
Scleroderma is a systemic autoimmune disease that can not be cured, the progression of the disease still difficult to prevent and lead to increased morbidity and mortality. Disease-modifying anti-rheumatic drugs (DMARDs) as standard immunosuppressant drugs to reduce, eliminate, inhibit inflammation and fibrosis in scleroderma patient is still less effective.
Objectives.
To evaluate the effect of ethanol extract of Physalis angulate Linn to reduce skin fibrosis based on MRSS, ESR, BAFF, sCD40L, and P1NP in scleroderma patients with standard therapy
Methods.
A Randomized, Double-Blind, Placebo-Controlled Clinical Trial on scleroderma patients with standard therapy, who admitted to Cipto Mangunkusumo Hospital Jakarta and Hasan Sadikin Hospital Bandung, from January 2016 to July 2017.
Patients must be controlled every month until three months for follow up. Subjects were divided into two parallel group, one of intervention group, and one of placebo group
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Ethanol extract of physalis angulate Linn with dosage of 3x250 mg/day given orally for 3 months
Other names: Herba Ciplukan, Ethanol extract of Physalis angulata Linn, Ethanol extract of Physalis angulata
No active component at the same dosage of 3x250 mg/day given orally for 3 months
Other names: Amylum
Time frame: 3 months of intervention
Clinical improvement of skin fibrosis in scleroderma patients measured by modified Improvement in skin fibrosis is defined if there is a significant reduced of mRSS.
Time frame: 3 months of intervention
Improvement is defined if there is a significant reduced of P1NP serum level
Time frame: 3 months of intervention
Improvement is defined if there is a significant reduced of ESR value
Time frame: 3 months of intervention
Improvement is defined if there is a significant reduced of BAFF serum level
Time frame: 3 months of intervention
Improvement is defined if there is a significant reduced of sCD40L serum level.
Indonesia University
Other
The Effect of Ethanol Extract Physalis Angulata Linn. in Scleroderma Patients With Standard Therapy to Reduce Skin Fibrosis Based on Modified Rodnan Skin Score, Reduce Inflammation, Immunological Response and Fibrosis
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03222492
Connective Tissue Diseases, Diffuse Cutaneous Systemic Sclerosis
Los Angeles, California, United States
View Trial DetailsNCT05204355
Connective Tissue Diseases, Scleroderma
Kansas City, Kansas, United States
View Trial DetailsNCT05995626
Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Omaha, Nebraska, United States
View Trial DetailsNCT03207997
Connective Tissue Diseases, Fibrosis
Paris, France
View Trial Details